SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (1461)2/3/1997 12:20:00 AM
From: Elllk   of 4342
 
The problem with the study on Androvir and AZT is that it was in vitro not in vivo, and I think that remains the case. An in vivo study remains to be done, although information may be forth coming when Androvir goes to market. I think many of the current cocktails contain AZT and a protease inhibitor, and various other medications--I don't think there is one standard cocktail. When Androvir goes to market, since it is safe, many current users of various cocktails will probably add Androvir on their own and hopefully much good and usefull data will come from that.

I believe severe nausea is one of the side effects which often results from AZT. Some AIDS groups and researchers, however, are convinced that AZT itself is so toxic that in many instances it does more to hasten deterioration and death then to slow them down. It probably is the case that in some it is helpful and others harmful, for idiosyncratic reasons, as with chemotherapy for leukemia or lymphoma where the hope is to kill the cancer before killing the patient. Hopefully, Androvir or cocktails involving Androvir can tip the scales further in the direction of therapeutic results with much reduced side effects. Again however, as far as I know, Androvir has not yet been tested with AZT in vivo.

Larry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext